NASDAQ$GRAL
Grail Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Grail Inc reported Q1 2025 results with strong Galleri test growth and narrowed losses.
Grail Inc delivered Q1 revenue of $31.8M, driven by Galleri test growth, while reporting a net loss of $106.2M. Adjusted EBITDA improved significantly year-over-year. The company maintains a strong cash position to support operations through 2028.
- Galleri test revenue grew 24% YoY to $29.1M with over 37,000 tests completed.
- Total revenue reached $31.8M, up 19% YoY.
- Net loss narrowed to $106.2M from $218.9M the prior year.
- Cash and equivalents totaled $677.9M, providing runway into 2028.
Headline financials
Revenue & EPS history
Grail Inc · Revenue · Quarterly
$31.8M
Revenue by segment
Grail Inc · $26.7M total across 2 segments · Q1 2024
- Screening revenue$23.5M—88.1%
- Development services$3.18M—11.9%
Forward guidance
Grail anticipates continued growth in Galleri test adoption and aims to file premarket approval in 2026 based on NHS-Galleri trial results.
Tailwinds
- Strong Galleri adoption with over 37,000 tests completed.
- Improved adjusted EBITDA and net loss YoY.
- High PPV, CSO accuracy, and specificity in NHS-Galleri trial.
- Integration with athenahealth to streamline ordering.
- Educational initiative with public figures to raise awareness.
Headwinds
- Continued net and operating losses despite improvements.
- No reported free cash flow data.
- Development services revenue declined YoY.
- Still awaiting final NHS-Galleri trial results (due mid-2026).
- Galleri test not yet FDA approved.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q1 2025
-4.0%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+4.5%
Avg return
30 days after
50%
4 / 8 earnings
Positive
+4.8%
Q3 2023
Best reaction
-23.6%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.8% | +12.5% | +10.2% | |
| Q3 2025 | -1.9% | -3.9% | +7.1% | |
| Q1 2025 | -23.6% | -10.9% | -3.7% | |
| Q4 2024 | -14.7% | -8.1% | -36.6% | |
| Q3 2023 | +4.8% | -7.2% | +46.9% | |
| Q3 2024 | +4.1% | -3.3% | +35.8% | |
| Q2 2023 | +0.1% | +9.0% | -11.8% | |
| Q2 2024 | +0.1% | +9.0% | -11.8% | |
| Q1 2024 | — | — | — | |
| Q4 2023 | — | — | — | |
| Q1 2023 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q3 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro